Anticoagulation Bests Antiplatelets After Mitral TEER in AF
This network meta-analysis pools sparse observational data suggesting oral anticoagulation, especially DOACs, reduces bleeding and mortality versus antiplatelet therapy after transcatheter mitral edge-to-edge repair in atrial fibrillation.
OAC strategies may reduce bleeding risk post-TMVR.
Determining optimal antithrombotic therapy post-transcatheter mitral valve repair (TMVR) in atrial fibrillation is crucial for balancing thrombotic and bleeding risks. Oral anticoagulants (OAC) reduced bleeding risk compared to antiplatelet therapy (APT), with phenprocoumon showing better ischemic stroke prevention. The study suggests OAC may be preferable to APT, but results are from observational cohorts, highlighting the need for randomized trials. OAC may offer better outcomes than APT post-TMVR in atrial fibrillation.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Citation:Zhu F, Yu Z, He Z Efficacy and safety of different antithrombotic treatment regimens in patients undergoing transcatheter mitral valve repair and atrial fibrillation; A meta-analysis and systematic review. Frontiers in cardiovascular medicine. 2026;13:1743097. doi:10.3389/fcvm.2026.1743097
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.